- ongoing, recruitingTherapeutic exploratory (Phase II)
J4E-MC-IMMB: A Master Protocol for Randomized, Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis; J4E-MC-FR01: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis
This study is looking into new ways to treat adults with moderate to severe eczema (atopic dermatitis). Researchers want to see how well a new medicine, LY3454738, works and if it's safe. They will compare it to a dummy treatment over 52 weeks.
Italy · Poland · Hungary - active not recruitingPHASE2
Seal, Stopping Eczema and Allergy Study
This study is for babies under 12 weeks old with early eczema. It compares special skin creams and treatments to standard care to see if they can reduce eczema and prevent food allergies. We want to find the best ways to keep young skin healthy.
United States · United Kingdom - recruitingPHASE2
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
This study is testing a new medicine, Galvokimig, for adults with moderate to severe eczema (atopic dermatitis). We want to find the best dose and check how well it works and if it's safe compared to a dummy drug.
United States · Bulgaria · Canada - ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis
This study is looking into a new medicine called Nemolizumab for children aged 2 to 11 who have moderate to severe eczema. It aims to see how safe the medicine is, how well it works, and how the body handles it. It's an important step in finding new ways to help children with eczema.
Hungary · Spain · Poland - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
This study looks at a new treatment called Lebrikizumab for adults and teenagers with moderate to severe eczema. We want to see how well it works and if it's safe. The main goal is to find out how many people see a big improvement in their eczema after 24 weeks.
Germany · Netherlands - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)
This study is testing a new medicine, rocatinlimab, for teenagers with moderate to severe eczema (atopic dermatitis). Researchers want to see if it's safe and helps improve their skin and reduce itching over 52 weeks, compared to a dummy treatment.
Croatia · Italy · Hungary - ongoing, recruitingTherapeutic confirmatory (Phase III)
J2T-MC-KGBI/DRM06-AD13: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis
This study is testing a new medicine called lebrikizumab for children and teenagers aged 6 months to under 18 years with moderate to severe eczema. We want to see if it helps improve their skin and is safe compared to a dummy medicine.
Poland · Spain · Czechia - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and exploratory clinical activity of NM26-2198 in healthy subjects and in patients with moderate-to-severe atopic dermatitis (AD)
This study is testing a new medicine, NM26-2198, for people with eczema (atopic dermatitis). It's a very early study to see if the medicine is safe and how it works in the body, both in healthy people and those with moderate to severe eczema.
Germany · Poland - active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
This study is testing a new medicine, baricitinib, for children and teenagers aged 2 to 17 with moderate to severe eczema. Researchers want to see if it's safe and helps improve their skin compared to a dummy pill or usual treatments.
Argentina · Australia · Austria - ongoing, recruitingTherapeutic confirmatory (Phase III)
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
This study is looking at the long-term safety and effectiveness of a new medicine called Lebrikizumab for adults and teenagers with moderate to severe eczema (atopic dermatitis). We want to see how well it works over two years and if there are any side effects.
Germany · Poland - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis
This study is looking at a new medicine called BMS-986326 for people with eczema (atopic dermatitis). Researchers want to see how a single dose works in the body at two different dose levels. It's an early-stage study to understand the medicine better.
Czechia · Germany · Spain - ongoing, recruitingTherapeutic confirmatory (Phase III)
I4V-MC-JAIP: A Phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
This study is looking at a new medicine called Baricitinib for children and teenagers with moderate to severe eczema. It wants to see if the medicine is safe and effective in helping their skin get better, compared to a dummy pill.
Hungary · Czechia · Poland - recruitingPHASE1
A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
This study compares a new medicine, CKD-706, with an existing one, Dupixent, in healthy adults. We're looking at how the body handles them, their effects, and safety to see if CKD-706 works similarly to Dupixent for conditions like eczema.
Germany · United Kingdom - recruiting
Mind and Skin - the Neurocutaneous Axis in Atopic Eczema
This study, called 'Mind and Skin,' looks at how severe eczema affects the brain, mental health, and thinking abilities in young people aged 12-18. It examines links between inflammation, itching, disturbed sleep, and how new eczema treatments might help.
United Kingdom - ongoing, recruitingTherapeutic confirmatory (Phase III)
18424-326: A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
This study is testing a new cream called ruxolitinib for adults with moderate eczema. It aims to see if the cream helps reduce eczema symptoms and itching by comparing it to a cream with no medicine. Researchers will check results after 8 weeks.
Spain · Italy · Poland - active not recruitingPHASE3
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
This study looks at the long-term safety of a treatment called dupilumab for children and teenagers with eczema (atopic dermatitis). It also checks how well it works and how the body handles the medicine over time. There's an optional part looking at a new way to give the medicine.
United States · Canada · Czechia - recruitingPHASE3
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
This study looks at two medicines, upadacitinib and dupilumab, for children aged 2 to 11 with moderate to severe eczema (atopic dermatitis). It wants to see which one works better and has fewer side effects for children who need strong treatment.
United States · Argentina · Australia - active not recruitingPHASE3
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
This study looks at a new combination treatment for teenagers and adults with moderate to severe eczema. It combines a new tablet called upadacitinib with steroid creams to see how well it works and if it's safe.
United States · Australia · Austria - recruitingPHASE3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
This study looks at a new drug called Tralokinumab for children and babies with moderate to severe eczema. We want to see if it's safe and helps when given with standard eczema creams. It could offer new hope for managing this condition.
United States · Belgium · Canada - active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
This study is testing a new cream called Ruxolitinib for children and teenagers aged 6 to 17 who have moderate eczema (atopic dermatitis). We want to see if it's safe and effective at reducing their skin symptoms. There's also a 'dummy' cream for comparison.
United States · Belgium · Canada - recruitingPHASE2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This study is looking into new ways to treat moderate to severe atopic dermatitis (eczema). It will test a new medicine called GHZ339 to see if it's safe and effective for adults. We want to find better options for people living with this skin condition.
United States · Argentina · Canada - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
This study is looking at a new medicine called Rocatinlimab for adults with moderate to severe eczema. We want to see if it helps improve skin, reduce itching, and is safe over 24 weeks compared to a dummy medicine.
Poland · Estonia · Denmark - ongoing, recruitingTherapeutic exploratory (Phase II)
A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.7881 in adult patients with moderate-to-severe atopic dermatitis
This study is testing a new tablet called BP1.7881 for moderate to severe eczema in adults. We want to see if it helps improve skin symptoms and itching, compared to a dummy tablet, over 12 weeks.
Germany · Poland · France - ongoing, recruitingTherapeutic exploratory (Phase II)
A phase 2b, randomised, double-blind, placebo-controlled, multi-site, parallel-group, dose finding trial to evaluate the efficacy and safety of different doses of subcutaneously administered LEO 138559 in adult subjects with moderate-to-severe atopic dermatitis (AD)
This study is testing a new medicine, LEO 138559, for moderate to severe eczema in adults. We want to see if different doses are safe and if they help improve eczema symptoms over 16 weeks compared to a dummy medicine.
Romania · Germany · France - recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
This study is testing a new medicine called IMG-007 for adults with moderate to severe eczema. Researchers want to see if it's safe and helps improve symptoms like itchy skin, compared to a dummy medicine.
United States · Canada - active not recruitingPHASE2
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
This study is testing a new medicine called Afimkibart for moderate to severe eczema in adults. Researchers want to see if it's safe and effective compared to a dummy treatment. It's a Phase 2 trial, meaning it's still early stage research.
United States · Brazil · Canada - authorisedTherapeutic exploratory (Phase II)
C6231002 - A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
This study is looking into a new medication for adults with moderate to severe eczema. It wants to see how well it works and if it's safe. Some people will get the new medicine, and others will get a dummy medicine to compare the effects.
Poland · Czechia · Germany - recruiting
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
This study looks at how Dupilumab works for people aged 6 and over with eczema in their daily lives. It aims to understand how the treatment affects their symptoms, quality of life, and overall control of their eczema over two years.
Germany - recruitingPHASE3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This study looks at a medicine called abrocitinib for children aged 2 and older with moderate to severe eczema. It checks how safe and effective it is over the long term, with some children having used it before and others trying it for the first time.
United States · China · Germany - active not recruitingPHASE3
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
This study looks at how well a new medicine, lebrikizumab, works and if it's safe for teenagers and adults with moderate to severe eczema. It wants to see if the medicine can improve skin symptoms over 24 weeks.
Germany · Netherlands · United Kingdom - recruiting
Molecular Signatures in Inflammatory Skin Disease
This study looks at people with skin conditions like eczema and psoriasis to understand how their bodies respond to new treatments. We want to find patterns in their genes and cells to help doctors choose the best medicine for each person in the future.
Germany - recruitingNA
Deployment o the Multidisciplinary Prospective Cohort Imminent
This study aims to better understand long-term inflammatory diseases like lupus and severe asthma. Researchers will collect information and samples to find new ways to treat these conditions, reduce side effects, and improve daily life for patients. It's about finding better treatments for the future.
France - recruiting
Microbiome in Atopic Dermatitis Under Systemic Therapy
This study looks at how new medicines for eczema affect the tiny living things (microbiome) on your skin. It helps us understand if the skin microbiome causes eczema or changes because of it, and if new treatments change it. This could lead to better ways to treat eczema.
Germany - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
This study is testing a new medicine called IMG-007 for adults with moderate to severe eczema (atopic dermatitis). We want to see if it's safe, how it moves through the body, and if it helps improve skin. Some people will get the medicine, others a dummy treatment.
Germany · Poland - active not recruitingPHASE3
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
This study is looking into a new medicine called lebrikizumab for children and teenagers aged 6 months to 17 years who have moderate to severe eczema. We want to see how well it works, if it's safe, and how the body handles it.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
A randomised controlled trial of a moisturiser for treatment of dry skin in atopic dermatitis: effect on the skin barrier in adults with a history of eczema
This study is looking at how well different moisturisers work to improve dry skin in adults who have a history of eczema. Researchers want to see if a new moisturiser can strengthen the skin's protective barrier compared to other treatments or no treatment at all.
Germany - recruiting
Frequency of Palpebral Involvement in Adult With Atopic Dermatitis
This study looks into how often eczema affects the eyelids and surrounding eye area. It aims to understand this better and improve treatments for people whose eczema causes problems around their eyes. The study will help us learn more about what causes eyelid eczema.
France - active not recruitingPHASE3
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
This study looks at the long-term effects of a new medicine, rocatinlimab, for teenagers and adults with moderate to severe eczema. It checks how safe and well-tolerated the medicine is, and if it continues to help over time.
United States · Argentina · Australia - recruiting
Characterization of Chronic Hand Eczema
This study looks at hand eczema and a similar skin condition called atopic dermatitis. Researchers want to understand these conditions better using gentle skin tests and scans. They will also see how these conditions affect people's daily lives over time.
Canada - not yet recruitingNA
Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults
This study compares a new emollient cream, Relipid+, with a widely used one, Lipikar Balm, for treating eczema (atopic dermatitis). We want to see if Relipid+ is just as good, especially for relieving symptoms and helping skin health for children and adults with mild to moderate eczema.
France - recruitingPHASE3
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
This study is looking at a new cream called tapinarof to treat eczema in babies and toddlers aged 3 months to under 2 years old. Researchers want to see if it's safe and helps improve their eczema compared to a cream without any medicine.
United States · Canada - active not recruitingPHASE2
A Study Evaluating TRIV-509 in Atopic Dermatitis
This study is testing a new medicine, TRIV-509, for adults with moderate to severe eczema (atopic dermatitis). It wants to see if the medicine helps improve eczema and if it's safe to use. Some people will get the medicine, others a dummy treatment, then they swap.
United States · Bulgaria · Canada - active not recruiting
A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
This study looks at how a medicine called upadacitinib (for a skin condition called atopic dermatitis or eczema) is used in real life. It checks how safe and effective it is for people aged 12 and over, seeing how long the good effects last outside of strict trial conditions.
Argentina · Australia · Austria - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
This study is testing a new medicine, ANB032, for people with moderate to severe eczema (atopic dermatitis). We want to see if it makes skin better and if it's safe to use, compared to a dummy treatment.
Poland · Czechia - recruitingPHASE2
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
This study is testing a new medicine, KT-621, for adults and teenagers with moderate to severe eczema (atopic dermatitis). We want to see if it's safe, helps reduce eczema symptoms, and how it works in the body. It involves comparing KT-621 to a dummy medicine.
United States · Australia · Canada - active not recruitingPHASE1
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
This study is looking at how safe and effective two new medicines (APG777 + APG990) are when used together for moderate to severe eczema, compared to an existing treatment (dupilumab).
Australia · Canada · New Zealand - recruitingNA
Meditation in Inflammatory Dermatosis
This study looks at how mindfulness meditation can help people with skin conditions like eczema and psoriasis. It aims to see if meditation can reduce itching, improve mood, and make skin less inflamed.
France - recruiting
French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
This study looks at how adults in France are treated for moderate to severe eczema (atopic dermatitis) with strong medicines. Doctors will observe patients' care for one year to understand how these treatments are used in real life.
France - recruitingPHASE2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
This study looks at a new medicine, APG777, for moderate-to-severe eczema (atopic dermatitis). It's for people who were in an earlier APG777 study and found the treatment helpful, to see if it's safe and works well over a longer time.
United States · Canada · Germany - authorisedTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated with Dupilumab.
This study is testing a new medicine, eblasakimab, for adults with moderate to severe eczema (atopic dermatitis) who have already tried a medicine called dupilumab. Researchers want to see if it helps improve their skin and is safe.
Poland · Germany